SEP 9, 2026 · JOURNAL ARTICLE
Venous Thromboembolism in Patients Receiving Vascular Endothelial Growth Factor-Targeted Therapy
Journal of Vascular Diseases
A comprehensive narrative review synthesizing evidence from trials, observational studies, and pharmacovigilance to provide clinical guidance on VTE risk, mechanisms, and management in VEGF-inhibitor-treated patients.
Reported
VTE incidence range2.5% to 15.7%
Relative risk (bevacizumab + chem…1.32–2.45